Albert David Stock Falls to 52-Week Low of Rs.738.95 Amidst Prolonged Downtrend

Recent Price Movement and Market Context

On 26 Dec 2025, Albert David’s stock price reached Rs.738.95, the lowest point in the last 52 weeks. Despite this, the stock outperformed its sector by 0.9% on the day, showing a modest gain after two consecutive days of decline. The price currently stands above its 5-day moving average but remains below the 20-day, 50-day, 100-day, and 200-day moving averages, indicating a longer-term bearish trend.

Meanwhile, the Sensex opened lower at 85,225.28, down by 183.42 points (-0.21%) and was trading near this level throughout the day. The benchmark index remains close to its 52-week high of 86,159.02, just 1.09% away, supported by mid-cap stocks which gained 0.2% today. This divergence highlights Albert David’s underperformance relative to the broader market.

Long-Term Price Performance

Over the past year, Albert David’s stock has recorded a return of -42.62%, a stark contrast to the Sensex’s positive 8.62% return during the same period. The stock’s 52-week high was Rs.1,412.15, nearly double the current price, underscoring the extent of the decline. This performance places Albert David among the weaker performers within the Pharmaceuticals & Biotechnology sector and the wider market.

Financial Performance and Profitability Trends

Albert David’s financial results over recent quarters have reflected ongoing pressures. The company has reported negative results for four consecutive quarters, with the latest six months’ profit after tax (PAT) at Rs.4.64 crores, showing a decline of 87.43% compared to previous periods. Profit before tax excluding other income (PBT less OI) for the latest quarter stood at a negative Rs.0.44 crores, falling by 109.80%.

Operating cash flow for the year is reported at a low of Rs.-28.44 crores, indicating cash outflows from core business activities. The company’s operating profit has shown a negative annual growth rate of 244.12% over the last five years, signalling challenges in sustaining profitability over the long term.

Valuation and Risk Considerations

The stock is considered to be trading at valuations that are risky relative to its historical averages. Over the past year, while the stock price has declined by 42.62%, profits have fallen by 122%, highlighting a disconnect between earnings performance and market valuation. Negative EBITDA further emphasises the financial strain on the company’s operations.

Despite these challenges, Albert David maintains a low average debt-to-equity ratio of zero, suggesting limited reliance on external borrowings. The majority shareholding remains with promoters, indicating concentrated ownership.

Sector and Market Comparison

Within the Pharmaceuticals & Biotechnology sector, Albert David’s performance has lagged behind broader indices such as the BSE500, underperforming over one year, three years, and the last three months. This underperformance is notable given the sector’s general resilience and growth prospects.

The Sensex’s current bullish positioning, trading above its 50-day moving average with the 50 DMA above the 200 DMA, contrasts with Albert David’s subdued technical indicators. This divergence highlights the stock’s relative weakness amid a generally positive market environment.

Summary of Key Metrics

To summarise, Albert David’s stock has reached a 52-week low of Rs.738.95, reflecting a year-long decline of 42.62%. The company’s financials show negative trends in profitability and cash flow, with operating profit and PAT declining significantly. The stock trades below most key moving averages, signalling continued pressure. Despite a low debt profile and promoter majority ownership, the stock’s valuation and earnings trajectory present challenges relative to sector peers and market benchmarks.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today